PSMA PET in prostate cancer

Journal of Nuclear Medicine

Volumn 56, Issue 8, 2015, Pages 1131-1132

  Jadvar, Hossein ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPROMAB PENDETIDE IN 111; CARBON 11; COPPER 64; FLUORINE 18; FLUOROCHOLINE F 18; GALLIUM 68; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM 86; ZIRCONIUM 89; EDETIC ACID; OLIGOPEPTIDE;

ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EDITORIAL; GLEASON SCORE; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN TARGETING; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MALE; MULTIMODAL IMAGING; PROSTATIC NEOPLASMS;

EDETIC ACID; HUMANS; MALE; MULTIMODAL IMAGING; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATECTOMY; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84938827015     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.157339     Document Type: Editorial

References (15)

1. Jadvar H. Molecular imaging of prostate cancer with PET. J Nucl Med. 2013;54:1685-1688.
2. Mease RC, Foss CA, Pomper MG. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem. 2013;13:951-962.
3. Demirkol MO, Acar O, Ucar B, et al. Prostate specific membrane antigen-based imaging in prostate cancer: impact on clinical decision making process. Prostate. 2015;75:748-757.
4. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
5. Bouchelouche K, Choyke PL, Capala J. Prostate specific membrane antigen: a target for imaging and therapy with radionuclides. Discov Med. 2010;9:55-61.
6. 68Ga]gallium-labeled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumor lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-495.
7. 68Ga-PSMA PET/CT. Clin Nucl Med. 2015;40:e163-e166.
8. 68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42:210-214.
9. 68Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdom Imaging. November 21, 2014 [Epub ahead of print].
10. 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674.
11. 18F-choline based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014; 41:11-20.
12. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48: 326-334.
13. 68Ga-labeled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
14. 223Ra therapy in a prostate cancer patient. Eur J Nucl Med Mol Imaging. 2015;42:362-363.
15. Baum RP, Kulkarni H, Weineisen M, et al. Advancing personalized nuclear medicine by theranostics of prostate cancer using Ga-68 and Lu-177 labeled PSMA small molecules. J Nucl Med. 2015;56(suppl. 1):22.